Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NL-OMON44385Recruiting
Open-label, single-arm trial of 5-aminolevulinic acid, sponsored by Erasmus MC. Primary endpoint: Minimum effective dose of Gliolan. Started Mar 2018; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NL-OMON44385.